Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04622345 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04622345 is a Phase 2 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT04622345, a Phase 2 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
Interventions
- DRUG Placebo
- DRUG VSJ-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-11-21 |
| Est. Completion | 2021-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04622345
The ClinicalTrials.gov registry entry for NCT04622345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04622345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04622345 about?
NCT04622345 is a clinical study titled "Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies". The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
What is the current status of trial NCT04622345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2020-11-21. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT04622345?
The interventions under investigation include: Placebo (DRUG), VSJ-110 (DRUG).
Who is sponsoring clinical trial NCT04622345?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.